Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure.
The role of the kidney in sufentanil elimination or metabolism has not been defined. The effects of chronic renal failure (CRF) on the pharmacokinetic profile of sufentanil were evaluated in six adolescent patients undergoing renal transplantation, and these findings were compared with data from age-matched control patients with normal renal function who were undergoing other surgical procedures. Patients with CRF weighed significantly less than did the control patients (28.7 +/- 5.7 vs 44.7 +/- 12.9 kg [mean +/- SD]). Although there was no statistical difference in the rate of clearance or apparent volume of distribution and half-life between the two groups, clearance and half-life were more variable among patients with CRF. In these patients, therefore, sufentanil dose must be carefully administered based on responses elicited in individual patients.
Davis
P J
PJ
Department of Anesthesiology, Children's Hospital of Pittsburgh, PA 15213-3417.
Stiller
R L
RL
Cook
D R
DR
Brandom
B W
BW
Davin-Robinson
K A
KA
D000293:Adolescent; D002648:Child; D005283:Fentanyl / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D017409:Sufentanil
D017409:Sufentanil; D005283:Fentanyl